Lux Capital announced that Karen Eliadis is its new Chief Financial Offier. The company, headquartered in Palo Alto, California, is a venture capital firm with focus on seed and early state investments in the emerging tech sector.

The Lux Capital portfolio consists of companies such as Caliper, Genocea, Illumina, Kala, Lux Research, Nanosys, Neurocrine Biosciences, Vertex Pharma and others which started from scrath.

Eliadis' most recent work was at BlueRun Ventures where she held the same position. She was also previously Director of Finance of Sofinnova Ventures, a venture capital firm targeting life science and tech firms.

"We're proud to add Karen to the Lux team," said Lux Capital's co-founder and Managing Partner Peter Hebert.  "She's established herself as a leader in the venture capital finance community and her acumen and insights will be integral to Lux's continued expansion," he added.

Commenting on her new company, Eliadis stated, "Having been intimately involved in the venture industry for more than a decade, I have great admiration for the unique franchise Lux Capital has built."